Related Experiment Videos
Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters
R D Weeratna1, T Wu, S M Efler
1Coley Pharmaceutical Canada, Ottawa, ON, Canada.
Gene Therapy
|February 1, 2002
Summary
Gene therapy faces challenges from immune responses. Using a muscle-specific promoter in DNA vaccines prevented immune reactions against the gene product in mice, suggesting a way to improve gene therapy safety.
Area of Science:
- Immunology
- Molecular Biology
- Gene Therapy
Background:
- Gene therapy aims to correct genetic disorders but is often hindered by adverse immune responses to the therapeutic gene product.
- Immune responses to DNA vaccines are primarily initiated by antigen-presenting cells (APCs), even when myocytes are the main cells transfected.
Purpose of the Study:
- To investigate if abrogating immune responses is possible by using a tissue-specific promoter that restricts gene expression away from APCs.
- To evaluate the efficacy of a muscle-specific promoter in preventing immune responses in DNA vaccination.
Main Methods:
- Plasmid DNA vaccines encoding hepatitis B surface antigen (HBsAg) were constructed using either a cytomegaloviral (CMV) promoter or a human muscle creatine kinase (MCK) promoter.
- These DNA vaccines were administered to mice, and HBsAg-specific humoral and cell-mediated immune responses were assessed.
Main Results:
- Mice vaccinated with HBsAg DNA using the ubiquitous CMV promoter mounted significant HBsAg-specific immune responses.
- In contrast, mice vaccinated with HBsAg DNA utilizing the muscle-specific MCK promoter showed no induction of HBsAg-specific humoral or cell-mediated immunity.
Conclusions:
- Employing a tissue-specific promoter (MCK) that limits expression in antigen-presenting cells can effectively prevent unwanted immune responses to the gene product.
- This strategy holds potential for enhancing the safety and efficacy of gene therapy by enabling stable gene expression without immune interference.